Plus Therapeutics to Host Investor Call to Discuss Leptomeningeal Cancer Related Acquisition and Topline Clinical Trial Data from the FORESEE Trial

Plus Therapeutics Inc.
Plus Therapeutics Inc.

In This Article:

Company acquired all assets for the synergistic CNSide cerebrospinal fluid diagnostic portfolio

Company will summarize topline data from the FORESEE clinical trial planned for presentation at the
SNO/ASCO Meeting in August 2024

Management call scheduled for Thursday, May 9th, 2024 at 8:30 AM ET

AUSTIN, Texas, May 08, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces it will host an investor call on Thursday, May 9th, 2024 at 8:30 AM ET to discuss the strategic acquisition of the CNSide cerebrospinal fluid (CSF) testing assets.

During the call, President and Chief Executive Officer Dr. Marc H. Hedrick will discuss the rationale for the CNSide acquisition and an overview of the assets acquired. In addition, he will also provide key updates since the September 2023 sublicense of CNSide, including topline data from the FORESEE trial, subsequent publications, interim milestones, the Company's business plan to leverage the acquired assets and planned future milestones.

Conference Call and Webcast
Thursday, May 9, 2024 @ 8:30 AM ET
Dial-in Link: https://register.vevent.com/register/BIdc75c8a5a88c41c683b270235002d285
Webcast: https://edge.media-server.com/mmc/p/nor9kmxs

Participants may also pre-register any time before the call through the dial-in-link. Once registration is completed, participants will be provided a dial-in number with a personalized conference code to access the call. Please dial in 15 minutes prior to the start time.

Following the live call, a replay will be available on the Company’s website under the “For Investors” section. The webcast will be available on the Company’s website for 90 days following the live call.

About CNSide Test
CNSide is a laboratory developed test (LDT) based on proprietary quantitative tumor cell capture and detection method, paired with assays to identify actionable molecular treatment targets. Given the genetic changes that can occur as metastatic cancer spreads to the CNS, the evaluation of cerebrospinal fluid with CNSide provides a unique opportunity to identify biomarkers in patients with metastatic carcinoma or melanoma to help guide physicians in therapy selection. In addition, the quantitative tumor cell count assay can be used in a serial fashion to monitor the response to therapy more effectively than other current methods.

About FORESEE clinical trial
The FORESEE Study is a multi-center, prospective clinical trial enrolling patients with Breast or Non-Small Cell Lung Cancer (NSCLC) who have suspicious or confirmed Leptomeningeal Metastases (LM). Standard of Care methods to diagnose or assess the treatment response of LM (Clinical Evaluation, MRI and Cytology) have limited sensitivity and specificity. This creates challenges for physicians to manage LM or determine the best course of treatment. The goal of the FORESEE Study is to evaluate the performance of CNSide in monitoring the LM's response to treatment and to assess the impact of CNSide on treatment decisions made by Physicians.